CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes

PURPOSE. No effective therapy is available for unresectable soft tissue sarcomas (STS). This unmet clinical need has prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR-redirected cytokine-induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Leuci, Valeria, Donini, Chiara, Grignani, Giovanni, Rotolo, Ramona, Mesiano, Giulia, Fiorino, Erika, Gammaitoni, Loretta, D’Ambrosio, Lorenzo, Merlini, Alessandra, Landoni, Elisa, Medico, Enzo, Capellero, Sonia, Giraudo, Lidia, Cattaneo, Giulia, Iaia, Ilenia, Pignochino, Ymera, Basiricò, Marco, Vigna, Elisa, Pisacane, Alberto, Fagioli, Franca, Ferrone, Soldano, Aglietta, Massimo, Dotti, Gianpietro, Sangiolo, Dario
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710537/
https://ncbi.nlm.nih.gov/pubmed/32900797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0357
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados